KEAP
Available
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Recruiting
50,000 enrolled
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
137 enrolled 31 charts
Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza
Phase 1 Completed
38 enrolled 14 charts
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
Phase 1/2 Terminated
48 enrolled
Expanded Access to Navitoclax
No longer available
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Phase 1 Recruiting
100 enrolled
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
Phase 1/2 Terminated
51 enrolled 18 charts
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
Phase 1 Completed
232 enrolled
Study of INCB053914 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
97 enrolled 40 charts
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Phase 1 Withdrawn
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
Phase 1/2 Terminated
69 enrolled 34 charts
Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)
Phase 1/2 Completed
30 enrolled
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Phase 2 Completed
185 enrolled
Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies
Phase 1 Completed
20 enrolled
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
Phase 2 Completed
57 enrolled
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
Phase 3 Completed
130 enrolled 9 charts
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
Phase 1 Completed
31 enrolled
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor
Phase 2 Terminated
13 enrolled 14 charts